| Methods |
4‐week placebo run‐in; inclusion criteria= supine DBP 90‐115 mm Hg after run‐in; 6‐week double‐blind treatment |
| Participants |
Temocapril 20 mg: n=19(13 males,6 females); mean age=57.6(8.3) years; baseline SBP=162(22) mm Hg, DBP=98(9) mm Hg;
Placebo: n=11(8 males,3 females); mean age=56.1(5.6) years; baseline SBP=151(13) mm Hg, DBP=97(7) mm Hg |
| Interventions |
Temocapril 20 mg once daily;
Placebo;
administered between 7 AM and 8 AM |
| Outcomes |
Trough supine SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SD of change not reported, endpoint BP and SE reported, calculated endpoint SD from N and endpoint SE, imputed endpoint SD for SD of change; BP data from Table 1, p. 529; Jadad score=3; funding source= not reported |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
